HCA Healthcare, Inc.’s (HCA - Free Report) third-quarter 2020 adjusted earnings of $1.92 per share missed the Zacks Consensus Estimate by 28.6%. Further, the bottom line declined 13.9% year over year due to lower patient admissions and higher costs.
Quarterly Details
HCA Healthcare’s revenues of $13.3 billion beat the Zacks Consensus Estimate by 0.1%. The top line also improved 4.9% from the year-ago period.
Same facility equivalent admissions declined 9% year over year, while same facility admissions tumbled 3.8% year over year. However, same facility revenue per equivalent admission grew 14.8% year over year on account of higher acuity of patients treated and favorable payer mix witnessed in the third quarter.
Same facility inpatient surgeries and same facility outpatient surgeries slid 6.8% and 6.3%, respectively, year over year.
Salaries and benefits, supplies and other operating expenses inched up 0.6% year over year to $10.5 billion.
Adjusted EBITDA totaled $2.1 billion, down 10.2% year over year.
As of Sep 30, 2020, HCA Healthcare operated 187 hospitals.
Financial Update
As of Sep 30, 2020, the company had cash and cash equivalents of $6.6 billion, comparing favorably from the 2019-end figure of $621 million. Total assets came in at $51.02 billion as of Sep 30, 2020, up 13.2% from 2019-end level.
Total debt of nearly $31 billion as of Sep 30, 2020 decreased 8.2% from 2019-end level.
In the reported quarter, capex came in at $489 million minus acquisitions.
Cash flows provided by operating activities were $2.7 billion, up 27.8% year over year.
Zacks Rank & Peer Releases
HCA Healthcare currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Among other players from the medical space that have reported third-quarter earnings so far, the bottom-line results of UnitedHealth Group Incorporated (UNH - Free Report) and Tenet Healthcare Corporation (THC - Free Report) beat estimates.
Upcoming Q3 Release
Alexion Pharmaceuticals, Inc. has an Earnings ESP of +0.84% and a Zacks Rank #3. The company is scheduled to release third-quarter 2020 earnings on Oct 29.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
HCA Healthcare, Inc.’s (HCA - Free Report) third-quarter 2020 adjusted earnings of $1.92 per share missed the Zacks Consensus Estimate by 28.6%. Further, the bottom line declined 13.9% year over year due to lower patient admissions and higher costs.
Quarterly Details
HCA Healthcare’s revenues of $13.3 billion beat the Zacks Consensus Estimate by 0.1%. The top line also improved 4.9% from the year-ago period.
Same facility equivalent admissions declined 9% year over year, while same facility admissions tumbled 3.8% year over year. However, same facility revenue per equivalent admission grew 14.8% year over year on account of higher acuity of patients treated and favorable payer mix witnessed in the third quarter.
Same facility inpatient surgeries and same facility outpatient surgeries slid 6.8% and 6.3%, respectively, year over year.
Salaries and benefits, supplies and other operating expenses inched up 0.6% year over year to $10.5 billion.
Adjusted EBITDA totaled $2.1 billion, down 10.2% year over year.
As of Sep 30, 2020, HCA Healthcare operated 187 hospitals.
Financial Update
As of Sep 30, 2020, the company had cash and cash equivalents of $6.6 billion, comparing favorably from the 2019-end figure of $621 million. Total assets came in at $51.02 billion as of Sep 30, 2020, up 13.2% from 2019-end level.
Total debt of nearly $31 billion as of Sep 30, 2020 decreased 8.2% from 2019-end level.
In the reported quarter, capex came in at $489 million minus acquisitions.
Cash flows provided by operating activities were $2.7 billion, up 27.8% year over year.
Zacks Rank & Peer Releases
HCA Healthcare currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Among other players from the medical space that have reported third-quarter earnings so far, the bottom-line results of UnitedHealth Group Incorporated (UNH - Free Report) and Tenet Healthcare Corporation (THC - Free Report) beat estimates.
Upcoming Q3 Release
Alexion Pharmaceuticals, Inc. has an Earnings ESP of +0.84% and a Zacks Rank #3. The company is scheduled to release third-quarter 2020 earnings on Oct 29.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on UNH - FREE
Get the latest research report on THC - FREE
Get the latest research report on HCA - FREE